Media Center Investor Relations Overview Investor News Press Releases Company Statements Media Kit Events Stock Information Stock Quote & Chart Analyst Coverage Ownership Profile Financials SEC Filings Annual Reports Governance Governance Documents Committee Composition Investor Resources Investor FAQs Settlement Information Contact Us Investor Email Alerts Investor contact760-603-2331Email Media contact760-603-4679Email Event Details 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting Nov 7, 2025 Supporting Materials A qualitative study and conceptual model of patient experiences during and between hereditary angioedema attacks 281.7 KB Donidalorsen for the Treatment of Hereditary Angioedema 1-Year Results From the OASISplus Open-Label Extension Study 812.2 KB Impact Of Donidalorsen In Patients With Hereditary Angioedema By Baseline Attack Rate From OASISplus 910.4 KB Phase 2 Open-Label Extension Study Of Donidalorsen In Patients With Hereditary Angioedema A 4-Year Analysis 771.5 KB Real-world Impact of Long-term Prophylaxis on the Clinical Burden of Patients with Hereditary Angioedema 253.5 KB Switching to Donidalorsen for Hereditary Angioedema 1-Year Results From the Phase 3 OASISplus Study 620.3 KB
2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting Nov 7, 2025 Supporting Materials A qualitative study and conceptual model of patient experiences during and between hereditary angioedema attacks 281.7 KB Donidalorsen for the Treatment of Hereditary Angioedema 1-Year Results From the OASISplus Open-Label Extension Study 812.2 KB Impact Of Donidalorsen In Patients With Hereditary Angioedema By Baseline Attack Rate From OASISplus 910.4 KB Phase 2 Open-Label Extension Study Of Donidalorsen In Patients With Hereditary Angioedema A 4-Year Analysis 771.5 KB Real-world Impact of Long-term Prophylaxis on the Clinical Burden of Patients with Hereditary Angioedema 253.5 KB Switching to Donidalorsen for Hereditary Angioedema 1-Year Results From the Phase 3 OASISplus Study 620.3 KB
A qualitative study and conceptual model of patient experiences during and between hereditary angioedema attacks 281.7 KB
Donidalorsen for the Treatment of Hereditary Angioedema 1-Year Results From the OASISplus Open-Label Extension Study 812.2 KB
Impact Of Donidalorsen In Patients With Hereditary Angioedema By Baseline Attack Rate From OASISplus 910.4 KB
Phase 2 Open-Label Extension Study Of Donidalorsen In Patients With Hereditary Angioedema A 4-Year Analysis 771.5 KB
Real-world Impact of Long-term Prophylaxis on the Clinical Burden of Patients with Hereditary Angioedema 253.5 KB
Switching to Donidalorsen for Hereditary Angioedema 1-Year Results From the Phase 3 OASISplus Study 620.3 KB
